Immunome (IMNM) Competitors $12.02 -0.42 (-3.38%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends IMNM vs. MRUS, TWST, ACAD, VCEL, MOR, SWTX, KYMR, ZLAB, GMTX, and VERAShould you be buying Immunome stock or one of its competitors? The main competitors of Immunome include Merus (MRUS), Twist Bioscience (TWST), ACADIA Pharmaceuticals (ACAD), Vericel (VCEL), MorphoSys (MOR), SpringWorks Therapeutics (SWTX), Kymera Therapeutics (KYMR), Zai Lab (ZLAB), Gemini Therapeutics (GMTX), and Vera Therapeutics (VERA). These companies are all part of the "pharmaceutical products" industry. Immunome vs. Merus Twist Bioscience ACADIA Pharmaceuticals Vericel MorphoSys SpringWorks Therapeutics Kymera Therapeutics Zai Lab Gemini Therapeutics Vera Therapeutics Immunome (NASDAQ:IMNM) and Merus (NASDAQ:MRUS) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings, risk and community ranking. Does the media favor IMNM or MRUS? In the previous week, Merus had 7 more articles in the media than Immunome. MarketBeat recorded 12 mentions for Merus and 5 mentions for Immunome. Immunome's average media sentiment score of 1.31 beat Merus' score of 0.54 indicating that Immunome is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunome 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Merus 4 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Which has more volatility and risk, IMNM or MRUS? Immunome has a beta of 1.83, indicating that its share price is 83% more volatile than the S&P 500. Comparatively, Merus has a beta of 1.07, indicating that its share price is 7% more volatile than the S&P 500. Do insiders and institutionals have more ownership in IMNM or MRUS? 44.6% of Immunome shares are held by institutional investors. Comparatively, 96.1% of Merus shares are held by institutional investors. 8.6% of Immunome shares are held by insiders. Comparatively, 4.6% of Merus shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Do analysts prefer IMNM or MRUS? Immunome presently has a consensus target price of $28.83, indicating a potential upside of 139.88%. Merus has a consensus target price of $85.64, indicating a potential upside of 90.73%. Given Immunome's higher probable upside, equities analysts plainly believe Immunome is more favorable than Merus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immunome 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Merus 0 Sell rating(s) 0 Hold rating(s) 12 Buy rating(s) 2 Strong Buy rating(s) 3.14 Which has higher earnings and valuation, IMNM or MRUS? Immunome has higher earnings, but lower revenue than Merus. Merus is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunome$10.13M74.07-$106.81M-$8.11-1.48Merus$35.93M85.55-$154.94M-$3.95-11.37 Does the MarketBeat Community favor IMNM or MRUS? Merus received 322 more outperform votes than Immunome when rated by MarketBeat users. However, 73.81% of users gave Immunome an outperform vote while only 67.11% of users gave Merus an outperform vote. CompanyUnderperformOutperformImmunomeOutperform Votes3173.81% Underperform Votes1126.19% MerusOutperform Votes35367.11% Underperform Votes17332.89% Is IMNM or MRUS more profitable? Merus has a net margin of -680.61% compared to Immunome's net margin of -3,014.59%. Merus' return on equity of -38.89% beat Immunome's return on equity.Company Net Margins Return on Equity Return on Assets Immunome-3,014.59% -48.63% -41.62% Merus -680.61%-38.89%-31.16% SummaryMerus beats Immunome on 12 of the 19 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get Immunome News Delivered to You Automatically Sign up to receive the latest news and ratings for IMNM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMNM vs. The Competition Export to ExcelMetricImmunomePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$776.47M$6.85B$5.14B$9.31BDividend YieldN/A3.06%4.81%4.06%P/E Ratio-1.4810.80135.3117.54Price / Sales74.07287.861,260.42139.42Price / CashN/A56.6540.5837.95Price / Book4.345.394.884.92Net Income-$106.81M$152.04M$118.89M$225.78M7 Day Performance-14.39%-4.32%15.96%-1.56%1 Month Performance27.40%2.80%15.87%6.68%1 Year Performance55.10%17.30%34.78%22.48% Immunome Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMNMImmunome2.807 of 5 stars$12.02-3.4%$28.83+139.9%+59.4%$776.47M$10.13M-1.4840Short Interest ↓Positive NewsMRUSMerus2.9299 of 5 stars$42.78-0.1%$85.64+100.2%+77.9%$2.93B$43.95M-10.8437TWSTTwist Bioscience2.8772 of 5 stars$48.86+2.9%$51.90+6.2%+39.8%$2.90B$312.97M-13.19990ACADACADIA Pharmaceuticals3.9246 of 5 stars$17.35+0.5%$25.60+47.6%-39.1%$2.89B$726.44M22.13510VCELVericel0.8932 of 5 stars$57.97+0.9%$59.71+3.0%+54.0%$2.86B$226.84M957.83300Positive NewsMORMorphoSys0.0797 of 5 stars$18.96+2.4%$14.33-24.4%N/A$2.86B$238.28M-5.45730SWTXSpringWorks Therapeutics1.9318 of 5 stars$38.21-0.2%$69.50+81.9%+11.0%$2.84B$5.45M-9.87305Positive NewsKYMRKymera Therapeutics2.228 of 5 stars$43.73+3.8%$53.88+23.2%+62.2%$2.83B$87.56M-18.00170ZLABZai Lab2.5159 of 5 stars$26.06-1.0%$55.00+111.1%-10.1%$2.83B$355.75M-9.512,175GMTXGemini TherapeuticsN/A$64.89+1.0%N/A+12.7%$2.81BN/A-64.8930VERAVera Therapeutics3.5627 of 5 stars$44.38+0.7%$59.22+33.4%+174.4%$2.81BN/A-16.8840 Related Companies and Tools Related Companies MRUS Competitors TWST Competitors ACAD Competitors VCEL Competitors MOR Competitors SWTX Competitors KYMR Competitors ZLAB Competitors GMTX Competitors VERA Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IMNM) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunome, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunome With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
